Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 9/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | GSR | P00390 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10030647 | 1.00 | BCHE (0.59) | BCHEALDH1A1MAPTGSRCA2 | |
| SCHEMBL31538809 | 0.84 | BCHE (0.71) | BCHEALDH1A1MAPTGSRCA2 | |
| SCHEMBL3489939 | 0.84 | ALDH1A1 (0.75) | BCHEALDH1A1MAPTGSRCA2 | |
| SCHEMBL3494230 | 0.84 | ALDH1A1 (0.75) | BCHEALDH1A1MAPTGSRCA2 | |
| SCHEMBL3491545 | 0.84 | ALDH1A1 (0.75) | BCHEALDH1A1MAPTGSRCA2 | |
| SCHEMBL1483452 | 0.83 | BCHE (0.42) | BCHEALDH1A1MAPTROCK2ROCK1 | |
| SCHEMBL1483446 | 0.83 | BCHE (0.42) | BCHEALDH1A1MAPTROCK2ROCK1 | |
| SCHEMBL1483457 | 0.83 | BCHE (0.42) | BCHEALDH1A1MAPTROCK2ROCK1 | |
| SCHEMBL7413928 | 0.79 | ALDH1A1 (0.72) | BCHEALDH1A1MAPTGSRCA2 | |
| SCHEMBL7417455 | 0.79 | ALDH1A1 (0.72) | BCHEALDH1A1MAPTGSRCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367711-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120238608-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-09-20 | — | — | US | disclosed |
| US-8207208-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110065765-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238608-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, REN | BCHE 1913/4885ALDH1A1 2760/4885MAPT 3903/4885 |
| US-20110065765-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, REN | BCHE 1906/4885ALDH1A1 3141/4885MAPT 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.